-
The State University of New Jersey's Rutgers Business School has also been busy, carving out a niche by offering an MBA course specialising in pharmaceutical management.
CNN: Degrees go for specialist redesign
-
Walgreen's position is "foolish, it's absurd, and every employer and health plan in America knows that, " says Mark Merritt, president of the Pharmaceutical Care Management Association, an industry group.
FORBES: On The Cover/Top Stories
-
Yet a third article came from executives of Express Scripts, a Fortune 100 company that vies with CVS Caremark for dominance in the pharmaceutical benefit management business.
FORBES: Money and Power Embrace Patient Engagement
-
Model N makes revenue-management software for pharmaceutical and technology companies.
WSJ: Business Tech Deals Highlight IPO Slate
-
Among new listings, Model N surged 4.48, or 29%, to 19.98, after the company, which makes revenue-management software for pharmaceutical and technology companies, sold more shares at a higher price than it had originally indicated.
WSJ: Blue Chips Climb for Second Straight Day
-
The author of the proposal, Thomas Shrager, a partner at Tweedy, Browne, a money manager in New York City, has lobbied Bayer's management for months to free its undervalued pharmaceutical business from the rest of the conglomerate.
FORBES: A headache in Leverkusen
-
"There is good evidence for the efficacy of Orlistat (Alli) in weight reduction but it should not be used as the sole element of weight management, " says Dr Colin Cable of the Royal Pharmaceutical Society of Great Britain, who reviewed the products.
BBC: Slimming pills: Do the claims add up?
-
One of the four drugs used on this horse was a common form phenylbutazone that you probably recognize as as a Non-steroidal anti-inflammatory drug used for pain management in horses as ubiquitously used only through veterinarian controlled pharmaceutical sale to horse owner or trainer.
FORBES: Ann Romney Loves Me Not
-
With that said, the pharmaceutical sector is still showing some strength lately, says Greg Ghodsi, head of the Wealth Management Group at Raymond James.
FORBES: Intelligent Investing Panel
-
Akorn is a niche generic pharmaceutical company that develops, manufactures and markets pharmaceutical products in the areas of ophthalmology, antidotes and anti-infectives in addition to controlled substances for pain management and anesthesia.
FORBES: Akorn Stock Has Healthy Upside